PYREFIN

Pyrefin is a development-stage pharmaceutical company focused on producing EP2 receptor antagonists. The drugs Pyrefin is testing have myriad potential uses, including treatment for epileptic seizures. Rodent trials have shown efficacy in treatment for seizure-induced brain injury, endometriosis, and osteoarthritis without behavioral or organ toxicity after 30 days. Phase 1A of GRA’s venture development support focused Pyrefin’s team on prioritizing the clinical use of its treatment.